MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY for MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
HR 1919 Safeguarding America's Pharmaceutical Act of 2013 and the Senate "track and trace" legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Health Issues HCR
Implementation of the new health care reform law -- PL 111-148, specifically with regard to those provisions impacting Medicare/Medicaid prescription drug coverage in the essential benefit pkg., and other matters.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Budget/Appropriations BUD
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033 In all of the above the specific issues include potential Medicare offsets that might be applied to prescription drugs
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Medicare/Medicaid MMM
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014 H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY '15 through 2033In all of the above the specific issues include potential Medicare offsets that might be applied to prescription drugs, especially changes to ASP, physician payment and oncology matters.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARTI SHAH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.